Near-infrared optogenetic engineering of bacteria for cancer therapy.
No author listed
No abstract available
References:
Liu, B., Zhou, H., Tan, L., Siu, K. T. H. & Guan, X.-Y. Exploring treatment options in cancer: tumor treatment strategies. Sig. Transduct. Target. Ther. 9, 175 (2024). A review article that presents a comprehensive overview of emerging cancer therapies.
Zhou, S., Gravekamp, C., Bermudes, D. & Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727–743 (2018). A review article that presents the potential of engineered bacteria as a targeted delivery platform for cancer therapies.
Gurbatri, C. R., Arpaia, N. & Danino, T. Engineering bacteria as interactive cancer therapies. Science 378, 858–864 (2022). A review article that discusses the use of synthetic biology in optimizing bacterial therapies for cancer, focusing on enhancing therapeutic safety and effectiveness through engineered bacterial systems.
Gourinchas, G., Vide, U. & Winkler, A. Influence of the N-terminal segment and the PHY-tongue element on light-regulation in bacteriophytochromes. J. Biol. Chem. 294, 4498–4510 (2019). This paper reports the light-regulation mechanisms of chimeric photosensitive protein PadC4, which is an essential aspect of the NETMAP system.
Wilksch, J. J. et al. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression. PLoS Pathog. 7, e1002204 (2011). This paper reports that MrkH is a c-di-GMP-dependent transcriptional activator in Klebsiella pneumoniae.